WO2006112364A1 - Agent hypotenseur produit par la culture d’une bacterie lactique - Google Patents

Agent hypotenseur produit par la culture d’une bacterie lactique Download PDF

Info

Publication number
WO2006112364A1
WO2006112364A1 PCT/JP2006/307856 JP2006307856W WO2006112364A1 WO 2006112364 A1 WO2006112364 A1 WO 2006112364A1 JP 2006307856 W JP2006307856 W JP 2006307856W WO 2006112364 A1 WO2006112364 A1 WO 2006112364A1
Authority
WO
WIPO (PCT)
Prior art keywords
lactic acid
acid bacteria
blood pressure
culture
lowering agent
Prior art date
Application number
PCT/JP2006/307856
Other languages
English (en)
Japanese (ja)
Inventor
Keiichi Sadoyama
Takeshi Miyagi
Keiichiro Inafuku
Masaki Sakakibara
Tomohiro Hirahashi
Noritaka Yoshikawa
Original Assignee
Dainippon Ink And Chemicals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Ink And Chemicals, Inc. filed Critical Dainippon Ink And Chemicals, Inc.
Priority to JP2007526843A priority Critical patent/JP4762987B2/ja
Publication of WO2006112364A1 publication Critical patent/WO2006112364A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells

Definitions

  • Antihypertensive agent obtained by lactic acid bacteria culture
  • the present invention relates to an antihypertensive agent comprising a culture obtained by culturing lactic acid bacteria in a specific culture solution as an active ingredient.
  • Patent Document 3 a method of inoculating milk with lactobacilli
  • Patent Document 4 a method of inoculating milk products with enzymes and then lactic acid bacteria
  • Patent Document 5 a method of immersing rice bran or rice bran containing germ under certain conditions in water
  • Patent Document 1 Japanese Laid-Open Patent Publication No. 2004-081206
  • Patent Document 2 Japanese Patent Laid-Open No. 63-157963
  • Patent Document 3 PR No. 3172150
  • Patent Document 4 Japanese Patent Laid-Open No. 2001-120179
  • Patent Document 5 Patent 2590423
  • An object of the present invention is to provide an antihypertensive agent comprising, as an active ingredient, a lactic acid bacteria culture obtained by culturing lactic acid bacteria in a culture solution containing microalgae and lactic acid bacteria. Means for solving the problem
  • the present inventors maintain a microalgae and lactic acid bacteria in the presence of water, and obtain a lactic acid bacteria culture obtained by culturing the lactic acid bacteria in the mixture under various conditions.
  • a blood pressure lowering effect was tested, it was found that the culture had a very excellent action, and the present invention was completed.
  • the present invention provides an antihypertensive agent comprising a lactic acid bacterium culture obtained by culturing lactic acid bacteria in a culture solution containing microalgae and lactic acid bacteria as an active ingredient.
  • a lactic acid bacterium culture obtained by culturing lactic acid bacteria in a culture solution containing microalgae and lactic acid bacteria as an active ingredient.
  • a blood pressure-lowering agent containing as an active ingredient a lactic acid bacteria culture obtained by culturing lactic acid bacteria in a culture solution containing microalgae and lactic acid bacteria.
  • FIG. 1 is a graph showing a comparison of GABA amounts (mg / 100 g) of Example 1 and Example 2 up to a culture time of 24 hours.
  • FIG. 2 is a graph showing the rate of blood pressure increase at week X with reference to blood pressure at week 0. (Examination example)
  • microalgae used in the present invention examples include spirulina and chlorella.
  • Spirulina is a fine single-celled microorganism belonging to the genus Arthrospira and Spirulina, which has been included in cyanobacteria and has been collectively referred to as the genus Spirulina.
  • Arusurosubira 'platensis Ar throspira platensis
  • Anoresurosuhifu' Ma 3 r Shima Ar throspira platensis
  • Anoresurosuhifu' Ma 3 r Shima Ar throspira platensis
  • Anoresurosuhifu' Ma 3 r Shima Ar throspira platensis
  • Anoresurosuhifu' Ma 3 r Shima (Arthrospira maxima, Anoresu Rosupira-Geitoreri (Arthrospira geitleri), Arusurosupira-Saiamize (Arthros pira Siamese)
  • Spirulina ' Mayer Spirulina major
  • Spirulina Sabusarusa Spirulina subsalsa
  • Gatorelli Alsrosvilla Siamese are preferred.
  • chlorella used in the present invention examples include the following.
  • Chlorella is a green algae (Chlorophyceae), Chlorella genus (Chlorella) algae (Chlorella) (Chlorella), is easy to obtain and excellent in safety.
  • Chlorella 'Bulgaris C. Examples include 'Chlorella regularis', chlorella 'Pyrenoidosa', and chlorella 'C. ellipsidea'.
  • microalgae examples include raw alga bodies, dried alga bodies, and processed alga bodies processed by a method such as mechanical treatment.
  • the raw algal bodies can be obtained, for example, by harvesting spirulina or chlorella cultured in water by a method such as centrifugation or filtration.
  • Raw algal cells can be used as they are after harvesting, but it is preferable to wash them with water or saline!
  • Examples of the dried alga body include those obtained by freeze-drying or spray-drying the raw alga body obtained by the above method.
  • the processed alga body treated by the mechanical treatment method can be obtained, for example, by subjecting raw alga bodies to ultrasonic treatment or mechanical treatment such as homogenization.
  • the mechanically processed alga body may be subjected to a drying treatment thereafter.
  • the algal bodies used in the present invention are preferably raw algal bodies because they retain more active ingredients of microalgae, and are also preferable in terms of taste and smell.
  • Raw alga bodies are usually suspended in water depending on the degree of water removal during harvesting, pastes with less water content than suspended ones, There is a cake-like state in which the water content is less than that in the pasty state.
  • Spirulina and chlorella are preferably used in the form of suspended alga bodies (hereinafter sometimes referred to as suspension).
  • suspension when using dried algae or processed algae, it may be in a dry state, or it may be a suspension, paste or cake like raw algae by adding water. .
  • Microalgae should not be heat sterilized so as not to impair their active ingredients. Although it is preferable, what was heat-sterilized as needed can also be used.
  • spirulina or chlorella may be used alone, or a mixture of spirulina and chlorella may be used.
  • Lactic acid bacteria have long been used to process many foods, including fermented dairy products, brewed products, vegetables, and pickles of fruits, for the purpose of storing and seasoning foods.
  • any lactic acid bacteria that can be used for food can be used without limitation.
  • Lactic acid bacteria are classified into milk-based lactic acid bacteria, plant-based lactic acid bacteria, intestinal lactic acid bacteria, and lactic acid bacteria derived from natural lakes where algae grow, depending on the growth environment.
  • Lactic acid bacteria are classified into mesophilic bacteria, thermophilic bacteria, salt-tolerant bacteria, and the like depending on the optimal growth conditions, but bacteria having any property may be used.
  • the lactic acid bacteria used in the present invention are taxonomically classified as Lactobacillus, Pediococcus, Tetragenococcus, Carnobacterium, and Vagococcus.
  • Genus Leuconostoc genus, Weissella genus, Oenococcus genus, Atopobium genus, Streptococcus genus (official name is Enterococcus genus, and in this document, Enterococcus genus) ), Enterococcus
  • the lactic acid bacteria used in the present invention are preferably lactic acid bacteria belonging to the genus Lactobacillus, Ratatococcus, or Enterococcus.
  • Lactic acid bacteria may be used alone, or two or more bacteria may be mixed and used. . In the culture process described later, the same type of bacteria may be inoculated and cultured in two or more stages, or different bacterial species may be inoculated and cultured in two or more stages. Lactic acid bacteria can be stored after culturing in an agar medium or liquid medium, and then stored by refrigeration storage, frozen storage, dry storage, or other storage methods. It is used to inoculate and culture in a liquid medium (hereinafter abbreviated as “seed culture medium”). The ability to produce flavors such as acetaldehyde and diacetyl, which have a fast growth rate of lactic acid bacteria, and the ability to produce organic acids.
  • the medium used for cultivating the seed culture is not particularly limited as long as the lactic acid bacterium to be used can grow, but in general, as a liquid medium for culturing lactic acid bacteria, for example, MRS medium devised by Man, Rogosa, Sharpe ( And a whey medium and a skim milk medium using milk components.
  • a stored lactic acid bacterium is added to the liquid medium, and maintained in an aerobic state or an anaerobic state suitable for the lactic acid bacterium to be cultured, and left or stirred. Cultivate.
  • the lactic acid bacteria culture is prepared by culturing lactic acid bacteria in a culture solution containing microalgae and lactic acid bacteria.
  • the culture solution containing microalgae and lactic acid bacteria is not particularly limited as long as it contains microalgae and can grow lactic acid bacteria.
  • a suspension in which microalgae is suspended in water It can be obtained by a method of collecting lactic acid bacteria in the liquid, a moist liquid containing fine algae in water, a method of adding lactic acid bacteria to a paste, cake, etc., a method of adding the seed culture solution to the suspension, etc. Monkey.
  • (i) is preferred. Further, in (i), using a suspension of raw algal bodies as microalgae and using a culture solution, particularly a seed culture solution as lactic acid bacteria, is a culture of lactic acid bacteria. High performance and flavor production ability!
  • the algae suspension, paste, cake, and lactic acid bacteria culture solution contain water. If the culture solution containing microalgae and lactic acid bacteria is insufficient, add water to You may make it the state maintained underwater.
  • the water is preferably sterilized water.
  • the content of the microalgae in the culture solution containing the microalgae and lactic acid bacteria is 0.1 as dry cells from the viewpoint of improving efficiency in the harvesting and drying steps after lactic acid bacterium culture described below. -30% by mass is preferred 1-20% by mass is more preferred.
  • Cultivation of lactic acid bacteria in a culture solution containing microalgae and lactic acid bacteria may be stationary culture, or may be agitation culture with propeller stirring if the culture solution is liquid. Further, the culture system may be anaerobic or aerobic so as to be suitable for the growth of the lactobacillus used.
  • the amount of lactic acid bacteria used may be the number of bacteria in which lactic acid bacteria grow, but from the viewpoint of improving the suppression of the propagation of contaminating bacteria, the number of lactic acid bacteria at the start of cultivation of lactic acid bacteria is the algae in terms of solid content. It is preferred that there are 11 lC lO per class lg, more preferably 10 6 to 10 1 G.
  • the pH of the culture solution containing microalgae and lactic acid bacteria is a force that changes during the cultivation process due to acids such as lactic acid produced by culturing lactic acid bacteria.
  • the pH force at the start of culture is preferably 4.0 to 9.0. Mashima 5.0 to 7.0 is more preferable.
  • the culture temperature may be any temperature as long as the lactic acid bacteria can grow, but 4-45 ° C is preferred because it is suitable for the growth of lactic acid bacteria and the active ingredients of microalgae are not impaired. ° C is more preferred.
  • the culture time is sufficient to proliferate lactic acid bacteria and exert an excellent blood pressure lowering effect.
  • 9 to: L00 time is preferred 15 to 72 hours is more preferred 18 to 50 hours is particularly preferred It is preferable.
  • the number of lactic acid bacteria after culturing exerts an excellent blood pressure lowering effect, is sufficient to suppress the increase of other contaminants, reduces the taste and odor peculiar to microalgae, and exerts a blood pressure lowering effect. It is preferable that the number of lactic acid bacteria at the beginning is 10 to: L000 times.
  • a basic compound such as potassium hydroxide or potassium hydroxide may be added during the cultivation to adjust the pH.
  • Milk to produce It is preferable that the pH of the culture solution containing microalgae and lactic acid bacteria is lowered to around 5.0 due to acid or the like because it reduces impurities and exerts a blood pressure lowering effect.
  • the addition of sugar to a culture solution containing microalgae and lactic acid bacteria can suppress the growth of contaminating bacteria, and the smell and taste peculiar to microalgae. Is preferable because it can be further reduced. This inhibitory effect on the growth of germs is particularly prominent when the germs are easy to propagate as microalgae / and dried algae are used.
  • Examples of the saccharide include monosaccharides, oligosaccharides, and polysaccharides.
  • monosaccharides include glucose, galactose, mannose, fructose, ribose, xylose and the like.
  • Examples of the oligosaccharide include disaccharides such as sucrose and maltose, galatato-oligosaccharide, furato-oligosaccharide, soybean oligosaccharide, xylo-oligosaccharide, and raffinose.
  • Examples of the polysaccharide include amylose, amylopectin, cellulose, dalicogen, j8-glucan, mucopolysaccharide and the like.
  • an oligosaccharide is preferable, and among them, a galato-oligosaccharide and a xylo-oligosaccharide are preferable.
  • saccharides there are no particular restrictions on the method of adding saccharides.
  • microalgae, lactic acid bacteria, and saccharides may be mixed, or microalgae added with saccharides in advance and lactic acid bacteria may be mixed. Lactic acid bacteria added with sugars and microalgae may be mixed.
  • the saccharide may be solid, but it is preferable to use a saccharide previously dissolved in water or the like to form an aqueous solution.
  • the amount of saccharide used is preferably 0.05 to 20% by mass, more preferably 0.1 to 10% by mass, based on the total of the culture solution containing microalgae and lactic acid bacteria and the saccharide.
  • the lactic acid bacteria culture obtained as described above can be used as it is as a lactic acid bacteria beverage or a food supplemented with lactic acid bacteria.
  • the lactic acid bacteria culture obtained above has a characteristic that it has a component composition different from that of the raw powder of microalgae before cultivation.
  • the content per algal body lOOg is 10 times or more compared to that before culturing, and free amino acids
  • GABA ⁇ -aminobutyric acid
  • the amount of protein contained in the bulk powder before culturing treated with a separation membrane with a molecular weight of 10,000 and lactic acid bacteria culture is measured by the BCA (Bicincho ninic Acid) method, which is a general method for measuring protein amount. did.
  • BCA Bosseto ninic Acid
  • the component with a molecular weight of 10,000 or less increases about twice as much after 24 hours of culture compared to before the start of culture, and the high molecular weight protein is low. It was turned into a molecule and found to be a component with excellent absorbability.
  • the lactic acid culture obtained by the present invention is characterized by containing GABA at a high concentration as compared with the conventional lactic acid bacteria culture similar to the present invention.
  • GABA GABA
  • the lactic acid culture obtained by the present invention is characterized by containing GABA at a high concentration as compared with the conventional lactic acid bacteria culture similar to the present invention.
  • Patent Document 3 when L. lactis YIT 2027 is used alone in milk, it is 15 mg Zl00 mL after 3 days of culture, and mixed culture with L. casei YIT 9029 There is a description that increases to 38 mgZ 1 OOmL.
  • GABA can be produced at a concentration of lOOmgZlOOmL or more in a culture time of 24 hours, which is extremely excellent as a GABA production method.
  • the antihypertensive agent of the present invention comprises the lactic acid bacteria culture obtained above as an active ingredient.
  • the blood pressure lowering agent of the present invention can be prepared in the form of tablets such as naked tablets, film-coated tablets, sugar-coated tablets, enteric tablets, multilayer tablets, granules, powders, liquids and the like. Preparation into these forms may be carried out by suspending, drying, pulverizing, molding, etc. in the lactic acid bacteria culture according to a conventional method according to each form. In preparation for each form, binders, surfactants, thickeners, fillers, disintegrants, excipients and the like that are generally used for the preparation can be used. In addition, a strong lactic acid bacteria culture can be used as it is as a lactic acid bacteria beverage or a lactic acid bacteria additive, or the lactic acid bacteria culture can be added to other foods.
  • drying treatment when the drying treatment is performed, it is usually performed so that the moisture content of the algal bodies is 4 to 7% by mass, but a treatment capable of maintaining the number of lactic acid bacteria is preferable.
  • Preferable drying methods include, for example, freeze-drying method and spray-drying method. A drying method is more preferable.
  • the drying temperature during drying treatment increases the production efficiency as the exhaust air temperature is higher, but the quality of microalgae is good and the number of lactic acid bacteria does not decrease, so the product temperature is 30-70 ° C. It is preferable that the drying treatment is performed in a range of 40 to 60 ° C.
  • the product temperature refers to the sample temperature after drying.
  • the powder obtained above may be tableted by a known tableting method.
  • the powder obtained above may be dispersed in water, or the cultured lactic acid bacteria culture can be prepared as it is or diluted with water or the like.
  • the intake of the blood pressure lowering agent of the present invention to the patient is preferably determined in consideration of the patient's sex, age, symptom, etc., but is generally 0.2 to : LOg / day, especially 0.5 to 8 g / day is preferred. These may be taken together at one time, or the daily intake may be taken in several parts.
  • the inventors of the present invention confirmed the effect on hypertension, which is considered to be a major cause of various lifestyle-related diseases, using experimental animals. That is, spontaneously hypertensive rats (SHR strain) were mixed with spirulina lactic acid bacteria culture and chlorella lactic acid bacteria culture in solid feed, and after free intake, blood pressure was measured to confirm blood pressure lowering action.
  • SHR strain spontaneously hypertensive rats
  • a group fed with solid feed was set as the target group, and in addition, as a group fed with the test substance, a group of spirulina powder (test substance 1) mixed with the solid feed, spirulina lactic acid bacteria culture
  • test substance 1 a group of spirulina powder
  • test substance 2 a group of spirulina powder
  • test substance 3 a group of chlorella bulk powder
  • test substance 4 the group in which the chlorella lactic acid bacteria culture
  • the group fed with the spirulina lactic acid bacteria culture or the chlorella lactic acid bacteria culture has a stronger blood pressure lowering effect than the control group, the spirulina bulk powder, and the group fed with the chlorella bulk powder. (See test example).
  • mice 10 male and 10 female ddY-N mice (body weight 20-26 g) were used.
  • the administration method is that the culture can be finely pulverized and suspended in a CMC 1% solution. A suspension with a concentration of 10% by mass was orally gavaged once. The culture was observed for 1 week after administration. LD for both males and females is over 6, OOOmg / kg, confirming food safety.
  • a 2500 L culture tank was charged with 25 kg of galactooligosaccharide and 825 kg of tap water. After heat sterilization, 100 kg of spirulina powder was added and inoculated with 50 kg of a seed culture solution of lactic acid bacteria Lactobacillus brevis. Lactic acid bacteria were cultured with aeration propeller stirring at 37 ° C for 72 hours. The culture solution was sampled at culture times of 0, 9, 12, 15, 18, 24, 48, and 72 hours, and the number of lactic acid bacteria was measured.
  • the number of lactic acid bacteria was measured by the following procedure. Lactic acid bacteria culture solution 1. Oml was suspended in 19ml of phosphate buffered saline to prepare a suspension. The suspension further with phosphate-buffered saline, 10x, 10 twice, 10 three times, 10 4 times, 10 5 times, 10 6 times, and sample diluent was diluted to 10 7 times Got. MRS agar medium prepared by adding 15 g of agar to 1000 ml of MRS medium (Merck Cat. No. 10661) is smeared with 0.1 ml of diluent and cultured at 35 ° C for 48 hours. did. Using an agar medium in which 30 to 300 colonies of lactic acid bacteria were confirmed, the number of colonies in the agar medium was measured, and the number obtained by multiplying this number by the dilution factor was taken as the number of lactic acid bacteria.
  • each sampled culture solution was spray-dried and subjected to amino acid analysis.
  • Each 200 mg of Spirulina lactic acid bacteria culture was added to 5 mL of water, suspended, and left for 30 minutes.
  • the supernatant and insoluble material were separated by a centrifuge (3000 rpm, 10 minutes), and 1 mL of the supernatant was collected.
  • 1 mL of 10% (w / v) triclonal acetic acid solution was added and centrifuged.
  • the obtained supernatant was subjected to HPLC analysis by the 0-phthalaldehyde method (post-column detection) to measure the amount of amino acids.
  • Table 1 shows the amounts of L-glutamic acid, GABA, and lactic acid bacteria in the culture at each culture time.
  • lactic acid bacteria were cultured in the same manner as in Example 1 except that a 50% (w / w) lactic acid solution was used to maintain the pH at 5.0 and the culture temperature at 30 ° C.
  • the culture solution was sampled at culture times of 0, 9, 12, 15, 18, 21, and 24 hours, and the amount of GABA (mg / lOOg) was measured.
  • GABA amount (mg / lOOg) was measured in the same manner as in Example 2 except that xylo-oligosaccharide was used instead of galatato-oligosaccharide.
  • Example 1 A comparison of GABA amounts (mg / lOOg) between Example 1 and Example 2 up to a culture time of 24 hours is shown in FIG. 1, and the results of Example 2 and Example 3 are shown in Table 2.
  • Example 1 except that chlorella was used instead of Spirulina, a lactic acid bacteria culture was prepared in the same manner as in Example 1, and the number of lactic acid bacteria and the amount of amino acids were measured. Table 3 shows the amounts of L-glutamic acid, GABA, and lactic acid bacteria in the culture at each culture time.
  • Target group Solid feed MF (Made by Oriental Yeast Co., Ltd.)
  • Test substance 1 Spirulina bulk powder
  • Test substance 2 Lactic acid fermented spirulina (Lactic acid bacteria culture obtained in Example 1)
  • Test substance 3 Chlorella bulk powder
  • Test substance 4 Lactic acid fermentation chlorella (Lactic acid bacteria culture obtained in Example 4) (Test substance preparation and administration) Preparation method: Solid feed MF was mixed with 15% each of test substances 1-2.
  • Blood pressure was measured by the tail-cuff method, which measures blood pressure in the tail artery noninvasively. The measurement was performed before the test substance administration (week 7) and every week after administration. The blood pressure was measured at 8 points in total, 3 times each, and the average value was taken as the measurement value. Prior to the test, it was confirmed that the average value of the maximum blood pressure of the test animals was 160 mmHg or more on average for each animal.
  • Test substance 1 7 0 1 7 5 1 9 0 2 1 0 2 1 0
  • Rate of increase in blood pressure (%) (blood pressure at week X, blood pressure at week 0) I (blood pressure at week 0) X 100 (%) [3 ⁇ 45]
  • the spirulina lactic acid bacteria culture and the chlorella lactic acid bacteria culture were confirmed to have an effect of suppressing an increase in blood pressure as compared with the spirulina bulk powder and the chlorella bulk powder before culture, respectively.
  • the blood pressure increase of about 30% is observed in the subject group, whereas in spirulina and chlorella, the increase rate is suppressed to 20 to 25%.
  • the lactic acid fermented product of Chlorella and chlorella it is apparent that the lactic acid fermented product according to the present invention is suppressed to about 12 to 15%.
  • the present invention can be used in fields such as the pharmaceutical industry, health food, and food.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L’invention concerne un agent hypotenseur comprenant, en tant que principe actif, la culture d’une bactérie lactique qui est produite en cultivant la bactérie lactique dans un milieu de culture qui contient une micro-algue et la bactérie lactique.
PCT/JP2006/307856 2005-04-15 2006-04-13 Agent hypotenseur produit par la culture d’une bacterie lactique WO2006112364A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007526843A JP4762987B2 (ja) 2005-04-15 2006-04-13 乳酸菌培養により得られる血圧低下剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005118832 2005-04-15
JP2005-118832 2005-04-15

Publications (1)

Publication Number Publication Date
WO2006112364A1 true WO2006112364A1 (fr) 2006-10-26

Family

ID=37115086

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/307856 WO2006112364A1 (fr) 2005-04-15 2006-04-13 Agent hypotenseur produit par la culture d’une bacterie lactique

Country Status (4)

Country Link
JP (1) JP4762987B2 (fr)
KR (1) KR20080004515A (fr)
CN (1) CN101160136A (fr)
WO (1) WO2006112364A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010007331A2 (fr) * 2008-07-18 2010-01-21 Roquette Freres Composition de fibres indigestibles solubles et de microalgues utilisees dans le domaine du bien etre
FR2935228A1 (fr) * 2009-09-30 2010-03-05 Roquette Freres Composition de maltodextrines branchees et d'organismes eucaryotes dotes d'une paroi polysaccharidique utilisees dans le domaine du bien etre
WO2017216818A1 (fr) * 2016-06-17 2017-12-21 Ocean Farma Srl Croissance anaérobie de bactéries dans une algue unicellulaire
EP3567114A1 (fr) 2018-05-07 2019-11-13 OCEAN FARMA S.r.l Procédé de synthèse de nanoparticules d'argent à l'aide de souches probiotiques cultivées en algues, mélange ternaire ainsi obtenu et utilisations de ceux-ci

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102763809A (zh) * 2012-07-05 2012-11-07 昆明豪原特自控有限公司 一种生物饲料添加剂及其制备方法
KR102287187B1 (ko) * 2018-12-31 2021-08-06 재단법인 전남바이오산업진흥원 김 추출물을 유효성분으로 함유하는 프리바이오틱스 조성물 및 이의 용도

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538336A (en) * 1978-09-12 1980-03-17 Kurorera Kogyo Kk Extraction of hypotensive substance
JPS6245532A (ja) * 1985-08-23 1987-02-27 Nisshin Oil Mills Ltd:The 血圧上昇抑制剤
JPS63139129A (ja) * 1986-12-01 1988-06-10 Yakult Honsha Co Ltd 血圧降下剤
JPS63157963A (ja) * 1986-12-22 1988-06-30 Toshiyuki Ota クロレラ食品の製法
JPH0751057A (ja) * 1993-08-11 1995-02-28 Kawasaki Steel Corp 乳酸菌およびビフィズス菌の増殖促進物質含有物
JP2000102364A (ja) * 1998-09-29 2000-04-11 Minoru Yoneda スピルリナ機能発現食品
JP2002241305A (ja) * 2001-02-14 2002-08-28 Yakult Honsha Co Ltd 高血圧症予防・治療剤
JP2003088339A (ja) * 2001-09-19 2003-03-25 Kentekku:Kk スーパークロレラの製造方法
JP2004081206A (ja) * 2002-06-26 2004-03-18 Dainippon Ink & Chem Inc スピルリナの処理方法
JP2004357611A (ja) * 2003-06-05 2004-12-24 Masayasu Onishi おから可溶化液からなる培地とその製造方法、該培地を用いた微生物の培養方法及び有用物質の製造方法と食品素材

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63139127A (ja) * 1986-11-29 1988-06-10 Michiko Kamijo 水虫貼布剤

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538336A (en) * 1978-09-12 1980-03-17 Kurorera Kogyo Kk Extraction of hypotensive substance
JPS6245532A (ja) * 1985-08-23 1987-02-27 Nisshin Oil Mills Ltd:The 血圧上昇抑制剤
JPS63139129A (ja) * 1986-12-01 1988-06-10 Yakult Honsha Co Ltd 血圧降下剤
JPS63157963A (ja) * 1986-12-22 1988-06-30 Toshiyuki Ota クロレラ食品の製法
JPH0751057A (ja) * 1993-08-11 1995-02-28 Kawasaki Steel Corp 乳酸菌およびビフィズス菌の増殖促進物質含有物
JP2000102364A (ja) * 1998-09-29 2000-04-11 Minoru Yoneda スピルリナ機能発現食品
JP2002241305A (ja) * 2001-02-14 2002-08-28 Yakult Honsha Co Ltd 高血圧症予防・治療剤
JP2003088339A (ja) * 2001-09-19 2003-03-25 Kentekku:Kk スーパークロレラの製造方法
JP2004081206A (ja) * 2002-06-26 2004-03-18 Dainippon Ink & Chem Inc スピルリナの処理方法
JP2004357611A (ja) * 2003-06-05 2004-12-24 Masayasu Onishi おから可溶化液からなる培地とその製造方法、該培地を用いた微生物の培養方法及び有用物質の製造方法と食品素材

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IWATA K. ET AL.: "Effects of Spirulina platensis on blood pressure in rats", JOSHI EIYO DAIGAKU KIYO, no. 21, 1990, pages 63 - 70, XP003006890 *
NAKAMURA T. ET AL.: "Effect of gamma-Amino butyric Acid-rich Chlorella on Blood Pressure in Mildly Hypertensive Subjects", JPN. PHARMACOL. THER., vol. 28, no. 6, 2000, pages 529 - 533, XP003006889 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010007331A2 (fr) * 2008-07-18 2010-01-21 Roquette Freres Composition de fibres indigestibles solubles et de microalgues utilisees dans le domaine du bien etre
WO2010007332A2 (fr) * 2008-07-18 2010-01-21 Roquette Freres Composition de fibres indigestibles solubles et d'organismes eucaryotes dotes d'une paroi polysaccharidique utilisees dans le domaine du bien etre.
WO2010007331A3 (fr) * 2008-07-18 2010-04-08 Roquette Freres Composition de fibres indigestibles solubles et de microalgues utilisees dans le domaine du bien etre
WO2010007332A3 (fr) * 2008-07-18 2010-04-22 Roquette Freres Composition de maltodextrines branchees et d'organismes eucaryotes dotes d'une paroi polysaccharidique utilisees dans le domaine du bien etre
US9725585B2 (en) 2008-07-18 2017-08-08 Roquette Freres Composition of soluble indigestible fibers and of eukaryotic organisms with a polysaccharide wall, used in the well-being field
US9758644B2 (en) 2008-07-18 2017-09-12 Roquette Freres Composition of soluble indigestible fibre and of microalgae used in the well-being field
FR2935228A1 (fr) * 2009-09-30 2010-03-05 Roquette Freres Composition de maltodextrines branchees et d'organismes eucaryotes dotes d'une paroi polysaccharidique utilisees dans le domaine du bien etre
WO2017216818A1 (fr) * 2016-06-17 2017-12-21 Ocean Farma Srl Croissance anaérobie de bactéries dans une algue unicellulaire
EP3567114A1 (fr) 2018-05-07 2019-11-13 OCEAN FARMA S.r.l Procédé de synthèse de nanoparticules d'argent à l'aide de souches probiotiques cultivées en algues, mélange ternaire ainsi obtenu et utilisations de ceux-ci

Also Published As

Publication number Publication date
KR20080004515A (ko) 2008-01-09
CN101160136A (zh) 2008-04-09
JPWO2006112364A1 (ja) 2008-12-11
JP4762987B2 (ja) 2011-08-31

Similar Documents

Publication Publication Date Title
KR101363735B1 (ko) 유산균의 증식 촉진제 및 생잔성 향상제
KR20060135016A (ko) 유카 추출물, 퀼라야 추출물 및 유산균을 포함하는 조성물및 상기 조성물을 함유하는 음식물
JP6039638B2 (ja) アディポネクチン分泌促進及び／又は減少抑制剤
EA037388B1 (ru) Штамм lactobacillus paracasei для продуцирования линолевой кислоты с сопряженными связями, питательные и фармацевтические препараты, содержащие этот штамм, и их применение
US7326558B2 (en) Process for treating spirulina
CN107868769A (zh) 一种高活性双歧杆菌冻干菌粉生产方法及应用
JP4762987B2 (ja) 乳酸菌培養により得られる血圧低下剤
JP6923883B2 (ja) 栄養状態改善に使用するための組成物
JP2016065039A (ja) キサンチンオキシダーゼを阻害するのに用いられる新規酢酸菌およびグルコンアセトバクター菌株並びにそれらの代謝物
JP6955808B1 (ja) 蜂蜜発酵物の製造方法
US20190053527A1 (en) Method for preparing a probiotic powder using a two-in-one whey-containing nutrient medium
JPH0696537B2 (ja) 血清コレステロ−ル上昇抑制剤
CN107881133A (zh) 一种高活性双歧杆菌菌粉真空干燥生产工艺及应用
JP4499979B2 (ja) 病原菌感染抑制用組成物
JP2006298779A (ja) 乳酸菌培養により得られる抗アレルギー剤
JP2009125055A (ja) ビフィズス菌および乳酸菌の増殖促進剤
JP2008295348A (ja) 大豆発酵食品
JPH0515366A (ja) 乳酸菌およびビフイズス菌の増殖促進剤
DK2403822T3 (en) Use of DATEM in the production media for lactic acid bacteria
RU2273662C2 (ru) Консорциум микроорганизмов пробиотического действия
JP2004081206A (ja) スピルリナの処理方法
JP5329924B2 (ja) 乳酸菌含有発酵食品およびその製造方法
JP7267536B2 (ja) 乳酸醗酵ニンジンの製造方法
JP2006298778A (ja) 乳酸菌培養により得られる免疫活性賦活剤
Elghali et al. Variations on soymilk components during fermentation by Lactobacillus and Bifidobacterium strains

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680012013.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2007526843

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020077024509

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06731792

Country of ref document: EP

Kind code of ref document: A1